C-MER Medical Holdings Limited Fundamental Analysis
C-MER Medical Holdings Limited (3309.HK) shows weak financial fundamentals with a PE ratio of 11.90, profit margin of 5.16%, and ROE of 5.64%. The company generates $2.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 43.2/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 3309.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak3309.HK struggles to generate sufficient returns from assets.
Valuation Score
Excellent3309.HK trades at attractive valuation levels.
Growth Score
Weak3309.HK faces weak or negative growth trends.
Financial Health Score
Excellent3309.HK maintains a strong and stable balance sheet.
Profitability Score
Weak3309.HK struggles to sustain strong margins.
Key Financial Metrics
Is 3309.HK Expensive or Cheap?
P/E Ratio
3309.HK trades at 11.90 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 3309.HK's PEG of 0.05 indicates potential undervaluation.
Price to Book
The market values C-MER Medical Holdings Limited at 0.67 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 5.43 times EBITDA. This is generally considered low.
How Well Does 3309.HK Make Money?
Net Profit Margin
For every $100 in sales, C-MER Medical Holdings Limited keeps $5.16 as profit after all expenses.
Operating Margin
Core operations generate 8.60 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $5.64 in profit for every $100 of shareholder equity.
ROA
C-MER Medical Holdings Limited generates $3.67 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
C-MER Medical Holdings Limited produces operating cash flow of $290.46M, showing steady but balanced cash generation.
Free Cash Flow
C-MER Medical Holdings Limited generates strong free cash flow of $212.00M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.17 in free cash annually.
FCF Yield
3309.HK converts 17.46% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
11.90
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.05
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.67
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.62
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.24
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.43
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.06
vs 25 benchmark
ROA
Return on assets percentage
0.04
vs 25 benchmark
ROCE
Return on capital employed
0.07
vs 25 benchmark
How 3309.HK Stacks Against Its Sector Peers
| Metric | 3309.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 11.90 | 29.63 | Better (Cheaper) |
| ROE | 5.64% | 223.00% | Weak |
| Net Margin | 5.16% | -38669.00% (disorted) | Weak |
| Debt/Equity | 0.24 | 0.82 | Strong (Low Leverage) |
| Current Ratio | 1.43 | 4.30 | Neutral |
| ROA | 3.67% | -379.00% (disorted) | Weak |
3309.HK outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews C-MER Medical Holdings Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation